Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China

Diabetology & Metabolic Syndrome, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 16, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the presence of at least one cardiovascular (CVD) risk factor, underscoring its potential to elevate CVD in affected individuals. However, evidence linking MASLD subclinical coronary atherosclerosis remains scarce, and further investigations are necessary elucidate independent role varying severities as a factor. This study analyzed 7,507 participants aged ≥ 40 who underwent comprehensive health evaluations Shanghai Health Medical Center. Logistic regression analysis was utilized explore relationship between severity artery calcification (CAC). Correlation performed assess association CAC staging. After adjusting for established factors, showed significant with CAC, which intensified increasing severity. Among individuals hypertension, markedly correlated CAC. In contrast, non-hypertensive participants, only moderate severe were significantly associated while mild demonstrated no notable link, even after adjustment factors. Moreover, correlation revealed positive staging, indicating that higher aligned more advanced stages. highlighted independently atherosclerosis, irrespective traditional an urban eastern Chinese population without prior history atherosclerosis. The strongest associations observed MASLD, emphasizing importance assessing stratification.

Language: Английский

---

Towards a broader perspective on non-alcoholic fatty liver disease and coronary artery disease relationship: managing metabolic risk beyond genetics

European Journal of Preventive Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 17, 2025

Language: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk

Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 163 - 163

Published: Jan. 22, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is correlated with an increased cardiovascular risk, independent of other traditional risk factors. The mechanisms underlying this pathogenic link are complex yet remain incompletely elucidated. Among these, the most significant visceral adiposity, low-grade inflammation and oxidative stress, endothelial dysfunction, prothrombotic status, insulin resistance, dyslipidemia postprandial hyperlipemia, gut dysbiosis, genetic mutations. Cardiovascular diseases leading cause death in patients MASLD. These have incidence coronary artery disease, carotid structural functional cardiac abnormalities, valvulopathies, as well arrhythmias conduction disorders. In review, we present latest data on association between MASLD focusing that explain correlation these two pathologies. Given high rates morbidity mortality among MASLD, consider it imperative to raise awareness risks associated condition within general population. Further research essential clarify linked This understanding may facilitate identification new diagnostic prognostic biomarkers for patients, novel therapeutic targets.

Language: Английский

---

From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)

Published: March 8, 2025

The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic (MASLD) represents a significant evolution in the nomenclature of disease. This updated terminology emphasizes dysfunction as central criterion, offering greater precision and improved risk stratification. MASLD broadens scope classification by incorporating individuals with diverse profiles, including lean patients hepatic steatosis, aligns clinical practice multifactorial nature this condition. global adoption creates opportunities for standardization research settings, facilitating multicenter collaborations enhancing development diagnostic tools therapeutic strategies. However, new poses challenges, potential confusion during implementation, cultural linguistic barriers, integration MetALD, need educational initiatives targeting healthcare providers patients. Further efforts are required refine criteria, address implementation seamlessly incorporate into international coding systems. review evaluates key advantages ongoing challenges associated MASLD, providing comprehensive analysis its impact on practice, research, health

Language: Английский

---

The Intertwined Fate of Liver and Heart: Unravelling the Complex Relationship between Metabolic Dysfunction-associated Steatotic Liver Disease and Coronary Artery Disease

Journal of Medical Evidence, Journal Year: 2025, Volume and Issue: 6(1), P. 90 - 91

Published: Jan. 1, 2025

Language: Английский

---

MAFLD vs. MASLD: a year in review

Expert Review of Endocrinology & Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 12

Published: April 12, 2025

In 2023, metabolic dysfunction-associated steatotic liver disease (MASLD) was introduced following fatty (MAFLD). Both aim to address the limitations of nonalcoholic (NAFLD). This review analyzes similarities and differences between MAFLD MASLD, focusing on their impacts epidemiology, diagnosis, stigma, related diseases. Current evidence suggests that criteria effectively identify individuals at higher risk through a good balance sensitivity specificity. Moreover, is more generalizable term easily understood globally. The transition from NAFLD MASLD marks significant advance in understanding within hepatology. identifies homogeneous cohort patients with due dysfunction provides valuable framework for holistic, patient-centered management strategies consider various contributing factors improve health outcomes.

Language: Английский

---